发明名称 Benzothiazinone and benzoxazinone compounds
摘要 Q is -N=or CR<SUP>2 </SUP> X is S, O or NOR<SUP>3 </SUP> Y is -O-, -S-, -SO- or -SO<SUB>2</SUB>- R and R<SUP>1 </SUP>are each, independently, H, a substituted or unsubstituted aliphatic, aromatic, heteroaromatic or aralkyl group R<SUP>2 </SUP>is H or a substituent R<SUP>3 </SUP>is H, or -C(O)R<SUP>4 </SUP> R<SUP>4 </SUP>is a substituted or unsubstituted aliphatic or aromatic group n is an integer from 0 to 1 Chemical compounds having structural formula I and physiologically acceptable salts thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the tyrosine kinases, whose activity is inhibited by these chemical compounds, are involved in angiogenic processes. Thus, these chemical compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferation is a factor. These compounds can be used to treat cancer and hyperproliferative disorders.
申请公布号 US7049312(B1) 申请公布日期 2006.05.23
申请号 US20000585925 申请日期 2000.06.02
申请人 ABBOTT GMBH & CO. KG 发明人 RAFFERTY PAUL;CALDERWOOD DAVID;ARNOLD LEE;PASCUAL BEATRIZ GONZALEZ;MARTINEZ JOSE L. ORTEGO;PEREZ DE VEGA MARIA J.;FERNANDEZ ISABEL
分类号 C07D265/36;C07D513/04;A61K31/42;A61K31/425;A61K31/437;A61K31/538;A61K31/5383;A61K31/5415;A61K31/542;A61P1/00;A61P3/10;A61P5/14;A61P9/00;A61P9/10;A61P11/16;A61P15/00;A61P17/02;A61P17/06;A61P19/02;A61P21/04;A61P25/00;A61P27/02;A61P29/00;A61P35/00;A61P37/02;A61P37/06;A61P43/00;C07D;C07D279/16;C07D413/06;C07D413/12;C07D413/14;C07D417/00;C07D417/06;C07D417/12;C07D417/14;C07D471/04;C07D498/04 主分类号 C07D265/36
代理机构 代理人
主权项
地址